The DOI matches its Crossref record; 515 of the 515 references it cites were found in a registry or an index.
Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2
Abstract
Human CYP1A2 is one of the major CYPs in human liver and metabolizes a number of clinical drugs (e.g., clozapine, tacrine, tizanidine, and theophylline; n > 110), a number of procarcinogens (e.g., benzo[a]pyrene and aromatic amines), and several important endogenous compounds (e.g., steroids). CYP1A2 is subject to reversible and/or irreversible inhibition by a number of drugs, natural substances, and other compounds. The CYP1A gene cluster has been mapped on to chromosome 15q24.1, with close link between CYP1A1 and 1A2 sharing a common 5'-flanking region. The human CYP1A2 gene spans almost 7.8 kb comprising seven exons and six introns and codes a 515-residue protein with a molecular mass of 58,294 Da. The recently resolved CYP1A2 structure has a relatively compact, planar active site cavity that is highly adapted for the size and shape of its substrates. The architecture of the active site of 1A2 is characterized by multiple residues on helices F and I that constitutes two parallel substrate binding platforms on either side of the cavity. A large interindividual variability in the expression and activity of CYP1A2 has been observed, which is largely caused by genetic, epigenetic and environmental factors (e.g., smoking). CYP1A2 is primarily regulated by the aromatic hydrocarbon receptor (AhR) and CYP1A2 is induced through AhR-mediated transactivation following ligand binding and nuclear translocation. Induction or inhibition of CYP1A2 may provide partial explanation for some clinical drug interactions. To date, more than 15 variant alleles and a series of subvariants of the CYP1A2 gene have been identified and some of them have been associated with altered drug clearance and response and disease susceptibility. Further studies are warranted to explore the clinical and toxicological significance of altered CYP1A2 expression and activity caused by genetic, epigenetic, and environmental factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MicroRNAs: Target Recognition and Regulatory Functions
Bartel, D. P. (2009) · Cell · doi:10.1016/j.cell.2009.01.002 · Cited by 20,068 · cited 1×
“…are a family of small noncoding RNAs of ~22 nucleotides that regulate gene expression by targeting mRNAs in a sequence-specific manner, leading to the induction of translational repression and/or mRNA degradation (Ambros, 2004; Bartel, 2009; Carthew and Sontheimer, 2009; Winter et al., 2009).”
The functions of animal microRNAs
Ambros, V. (2004) · Nature · doi:10.1038/nature02871 · Cited by 10,728
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
MicroRNAs: small RNAs with a big role in gene regulation
He, L., & Hannon, G. J. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1379 · Cited by 7,118
Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J. P., Deng, H.-X., et al. (1993) · Nature · doi:10.1038/362059a0 · Cited by 7,062 · cited 1×
“…and fatal neurodegenerative disease caused by the degeneration of motor neurons of the cortex, brainstem, and spinal cord and mutations in the gene that produces the Cu/Zn superoxide dismutase-1 (EC 1.15.1.1) are associated with ~20% of familial ALS (Logroscino and Armon, 2007; Rosen et al., 1993).”
BackgroundInfluentialOrigins and Mechanisms of miRNAs and siRNAs
Carthew, R. W., & Sontheimer, E. J. (2009) · Cell · doi:10.1016/j.cell.2009.01.035 · Cited by 5,018
Many roads to maturity: microRNA biogenesis pathways and their regulation
Winter, J., Jung, S., Keller, S., Gregory, R. I., & Diederichs, S. (2009) · Nature Cell Biology · doi:10.1038/ncb0309-228 · Cited by 2,656
A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis
Bensimon, G., Lacomblez, L., & Meininger, V. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300901 · Cited by 2,233
Denison, M. S., & Nagy, S. R. (2003) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.100901.135828 · Cited by 1,895 · cited 2×
“Upon binding a ligand, after the replacement of its associated molecule with Arnt to form a heterodimer with the release of 90 kDa HSPs, AhR translocates into the nucleus (Figure 17) (Denison and Nagy, 2003).”
BackgroundPhillips, P. C. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2452 · Cited by 1,575
Lee, Y. S., & Dutta, A. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092222 · Cited by 1,505
High-resolution crystal structure of cytochrome P450cam
Poulos, T. L., Finzel, B. C., & Howard, A. J. (1987) · Journal of Molecular Biology · doi:10.1016/0022-2836(87)90190-2 · Cited by 1,411
The Evolution of Transcriptional Regulation in Eukaryotes
Wray, G. A. (2003) · Molecular Biology and Evolution · doi:10.1093/molbev/msg140 · Cited by 1,222
Gotoh, O. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)48462-1 · Cited by 1,194
Nebert, D. W., Dalton, T. P., Okey, A. B., & Gonzalez, F. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.r400004200 · Cited by 1,182
Ingelman-Sundberg, M., Sim, S. C., Gomez, A., & Rodriguez-Antona, C. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.09.004 · Cited by 1,166
Coffee and Health: A Review of Recent Human Research
Higdon, J. V., & Frei, B. (2006) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408390500400009 · Cited by 1,090 · cited 1×
“Caffeine Caffeine (1,3,7-Trimethylxanthine, 137X), a purine alkaloid that occurs naturally in coffee beans, is widely consumed in beverages to obtain mild central nervous system stimulant effects (Higdon and Frei, 2006).”
BackgroundVanherweghem, J.-L., Tielemans, C., Abramowicz, D., Depierreux, M., Vanhaelen-Fastre, R., Vanhaelen, M., Dratwa, M., Richard, C., Vandervelde, D., Verbeelen, D., et al. (1993) · The Lancet · doi:10.1016/0140-6736(93)92984-2 · Cited by 1,076
MicroRNA Control in the Immune System: Basic Principles
Xiao, C., & Rajewsky, K. (2009) · Cell · doi:10.1016/j.cell.2008.12.027 · Cited by 1,018
Generation of a Set of Simple, Interpretable ADMET Rules of Thumb
Gleeson, M. P. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701122q · Cited by 969
Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1.
Shimada, T., Hayes, C. L., Yamazaki, H., Amin, S., Hecht, S. S., Guengerich, F. P., & Sutter, T. R. (1996) · PubMed · Cited by 895
The 2.6-A crystal structure of Pseudomonas putida cytochrome P-450.
Poulos, T. L., Finzel, B. C., Gunsalus, I. C., Wagner, G. C., & Kraut, J. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36209-9 · Cited by 826
Polymorphism of human cytochrome P450 enzymes and its clinical impact
Zhou, S.-F., Liu, J.-P., & Chowbay, B. (2009) · Drug Metabolism Reviews · doi:10.1080/03602530902843483 · Cited by 826
Self-citationCrystal structure of human cytochrome P450 2C9 with bound warfarin
Williams, P. A., Cosme, J., Ward, A., Angove, H. C., Matak Vinković, D., & Jhoti, H. (2003) · Nature · doi:10.1038/nature01862 · Cited by 821
Crystal Structures of Human Cytochrome P450 3A4 Bound to Metyrapone and Progesterone
Williams, P. A., Cosme, J., Vinković, D. M., Ward, A., Angove, H. C., Day, P. J., Vonrhein, C., Tickle, I. J., & Jhoti, H. (2004) · Science · doi:10.1126/science.1099736 · Cited by 806
Does Increased Access to Primary Care Reduce Hospital Readmissions?
Weinberger, M., Oddone, E. Z., & Henderson, W. G. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605303342206 · Cited by 800
Human P450 metabolism of warfarin
Kaminsky, L. S., & Zhang, Z.-Y. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(96)00140-4 · Cited by 798
Olanzapine versus Placebo and Haloperidol
Beasley, C. M., Tollefson, G., Tran, P., Satterlee, W., Sanger, T., & Hamilton, S. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00069-p · Cited by 778
Sachse, C., Brockmöller, J., Bauer, S., & Roots, I. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00898.x · Cited by 751
Yano, J. K., Wester, M. R., Schoch, G. A., Griffin, K. J., Stout, C. D., & Johnson, E. F. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c400293200 · Cited by 705
Mammalian Microsomal Cytochrome P450 Monooxygenase
Williams, P. A., Cosme, J., Sridhar, V., Johnson, E. F., & McRee, D. E. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)80408-6 · Cited by 696
Structure and function of cytochromes P450: a comparative analysis of three crystal structures
Hasemann, C. A., Kurumbail, R. G., Boddupalli, S. S., Peterson, J. A., & Deisenhofer, J. (1995) · Structure · doi:10.1016/s0969-2126(01)00134-4 · Cited by 692 · cited 25×
“As observed with other mammalian CYPs of known structures, the most conserved regions are the core of the protein forming the heme binding site and the proximal surface that is considered to offer binding sites for NADPHcytochrome P450 reductase and cytochrome b 5 .”
BackgroundInfluentialDrug Interactions with Tobacco Smoking: An Update
Zevin, S., & Benowitz, N. L. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936060-00004 · Cited by 692
Mega, J. L., Close, S. L., Wiviott, S. D., Shen, L., Hockett, R. D., Brandt, J. T., Walker, J. R., Antman, E. M., Macias, W. L., Braunwald, E., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.851949 · Cited by 651
Benzo[ a ]pyrene carcinogenicity is lost in mice lacking the aryl hydrocarbon receptor
Shimizu, Y., Nakatsuru, Y., Ichinose, M., Takahashi, Y., Kume, H., Mimura, J., Fujii-Kuriyama, Y., & Ishikawa, T. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.2.779 · Cited by 633
Failing the Public Health — Rofecoxib, Merck, and the FDA
Topol, E. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmp048286 · Cited by 599
Ward, B. A., Gorski, J. C., Jones, D. R., Hall, S. D., Flockhart, D. A., & Desta, Z. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.049601 · Cited by 593
Cytochrome P450 specificities of alkoxyresorufin O-dealkylation in human and rat liver
Burke, M. D., Thompson, S., Weaver, R. J., Wolf, C. R., & Mayers, R. T. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90363-8 · Cited by 554
Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs
Zhou, S., Yung Chan, S., Cher Goh, B., Chan, E., Duan, W., Huang, M., & McLeod, H. L. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544030-00005 · Cited by 517
Self-citationCoffee, CYP1A2 genotype, and risk of myocardial infarction
Cornelis, M. C., El-Sohemy, A., Kabagambe, E. K., & Campos, H. (2006) · JAMA · doi:10.1001/jama.295.10.1135 · Cited by 490 · cited 1×
“…infarction among individuals carrying the CYP1A2*1F allele, who are defined as PMs, in both smokers (n = 368 for the *1A/*1A genotype; n = 437 for the *1A/*1F or *1F/*1F genotype) and nonsmokers (n = 531 for the *1A/*1A genotype; n = 677 for the *1A/*1F or *1F/*1F genotype) (Cornelis et al., 2006).”
BackgroundSansen, S., Yano, J. K., Reynald, R. L., Schoch, G. A., Griffin, K. J., Stout, C. D., & Johnson, E. F. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611692200 · Cited by 478
Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention
Androutsopoulos, V. P., Tsatsakis, A. M., & Spandidos, D. A. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-187 · Cited by 476
Lee, A. J., Cai, M. X., Thomas, P. E., Conney, A. H., & Zhu, B. T. (2003) · Endocrinology · doi:10.1210/en.2003-0192 · Cited by 456
The Structure of Human Cytochrome P450 2C9 Complexed with Flurbiprofen at 2.0-Å Resolution
Wester, M. R., Yano, J. K., Schoch, G. A., Yang, C., Griffin, K. J., Stout, C. D., & Johnson, E. F. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405427200 · Cited by 440
Crystal Structure of Human Cytochrome P450 2D6
Rowland, P., Blaney, F. E., Smyth, M. G., Jones, J. J., Leydon, V. R., Oxbrow, A. K., Lewis, C. J., Tennant, M. G., Modi, S., Eggleston, D. S., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m511232200 · Cited by 437
Johansson, I., Oscarson, M., Yue, Q. Y., Bertilsson, L., Sjöqvist, F., & Ingelman-Sundberg, M. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09721-4 · Cited by 430
Butler, M. A., Lang, N. P., Young, J. F., Caporaso, N. E., Vineis, P., Hayes, R. B., Teitel, C. H., Massengill, J. P., Lawsen, M. F., & Kadlubar, F. F. (1992) · Pharmacogenetics · doi:10.1097/00008571-199206000-00003 · Cited by 419
MicroRNA Regulates the Expression of Human Cytochrome P450 1B1
Tsuchiya, Y., Nakajima, M., Takagi, S., Taniya, T., & Yokoi, T. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1403 · Cited by 408
A Controlled Trial of Tacrine in Alzheimer's Disease
Farlow, M. (1992) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1992.03490180055026 · Cited by 398
Interactions of Herbs with Cytochrome P450
Zhou, S., Gao, Y., Jiang, W., Huang, M., Xu, A., & Paxton, J. W. (2003) · Drug Metabolism Reviews · doi:10.1081/dmr-120018248 · Cited by 397
Self-citationKot, M., & Daniel, W. A. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.05.025 · Cited by 388
Effect of grapefruit juice on digoxin pharmacokinetics in humans
Becquemont, L., Verstuyft, C., Kerb, R., Brinkmann, U., Lebot, M., Jaillon, P., & Funck‐Brentano, C. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(01)17221-8 · Cited by 387
Structure of Human Microsomal Cytochrome P450 2C8
Schoch, G. A., Yano, J. K., Wester, M. R., Griffin, K. J., Stout, C. D., & Johnson, E. F. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312516200 · Cited by 382
Zhou, S.-F., Xue, C. C., Yu, X.-Q., Li, C., & Wang, G. (2007) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31815c16f5 · Cited by 375
Self-citationCloning and expression of a human Ah receptor cDNA.
Dolwick, K. M., Schmidt, J. V., Carver, L. A., Swanson, H. I., & Bradfield, C. A. (1993) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13282-3 · Cited by 348 · cited 1×
“The mRNA of AhR is dominantly expressed in the placenta, lung, heart, pancreas, and liver (Dolwick et al., 1993).”
BackgroundChemopreventive effects of natural dietary compounds on cancer development
Pan, M.-H., & Ho, C.-T. (2008) · Chemical Society Reviews · doi:10.1039/b801558a · Cited by 346
Nakajima, M., Yokoi, T., Mizutani, M., Kinoshitah, M., Funayama, M., & Kamataki, T. (1999) · Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a022352 · Cited by 346
Drug interactions with smoking
Kroon, L. A. (2007) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp060414 · Cited by 345
Treatment-Resistant Schizophrenia
Elkis, H. (2007) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2007.04.001 · Cited by 338
Madan, A., Graham, R. A., Carroll, K. M., Mudra, D. R., Burton, L. A., Krueger, L. A., Downey, A. D., Czerwinski, M., Forster, J., Ribadeneira, M. D., et al. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.4.421 · Cited by 338
Eagling, V. A., Tjia, J. F., & Back, D. J. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00679.x · Cited by 333
Haria, M., Fitton, A., & McTavish, D. (1994) · Drugs & Aging · doi:10.2165/00002512-199404040-00006 · Cited by 332
Dioxin binding activities of polymorphic forms of mouse and human arylhydrocarbon receptors.
Ema, M., Ohe, N., Suzuki, M., Mimura, J., Sogawa, K., Ikawa, S., & Fujii-Kuriyama, Y. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)46990-6 · Cited by 329 · cited 1×
“Cloning of human AhR cDNA revealed that it encodes a protein of 848 amino acid residues (Ema et al., 1994).”
BackgroundARNT-Deficient Mice and Placental Differentiation
Kozak, K. R., Abbott, B., & Hankinson, O. (1997) · Developmental Biology · doi:10.1006/dbio.1997.8758 · Cited by 328
Gu, L., Gonzalez, F. J., Kalow, W., & Tang, B. K. (1992) · Pharmacogenetics · doi:10.1097/00008571-199204000-00004 · Cited by 326
Yuan, R., Madani, S., Wei, X.-X., Reynolds, K., & Huang, S.-M. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.12.1311 · Cited by 325
Metabolism of melatonin by human cytochromes p450
Ma, X., Idle, J. R., Krausz, K. W., & Gonzalez, F. J. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.002410 · Cited by 319
Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2.
Tassaneeyakul, W., Birkett, D. J., Veronese, M. E., McManus, M. E., Tukey, R. H., Quattrochi, L. C., Gelboin, H. V., & Miners, J. O. (1993) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38136-x · Cited by 316
Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2* activities
Relling, M. V., Lin, J.-S., Ayers, G. D., & Evans, W. E. (1992) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1992.203 · Cited by 314
Fujisawa-Sehara, A., Sogawa, K., Yamane, M., & Fujii-Kuriyama, Y. (1987) · Nucleic Acids Research · doi:10.1093/nar/15.10.4179 · Cited by 313
Differential Metabolism of Gefitinib and Erlotinib by Human Cytochrome P450 Enzymes
Li, J., Zhao, M., He, P., Hidalgo, M., & Baker, S. D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0088 · Cited by 311
Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450
Diaz, D., Fabrev, I., Daujat, M., Aubert, B. S., Bories, P., Michel, H., & Maurel, P. (1990) · Gastroenterology · doi:10.1016/0016-5085(90)90963-2 · Cited by 308
Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test.
Bertilsson, L., Carrillo, J., Dahl, M.-L., LLerena, A., Alm, C., Bondesson, U., Lindström, L., de la Rubia, I. R., Ramos, S., & Benítez, J. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb04385.x · Cited by 307
A Review on Biological Control and Metabolism of Aflatoxin
Mishra, H. N., & Das, C. (2003) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408690390826518 · Cited by 305
Protective Interventions to Prevent Aflatoxin-Induced Carcinogenesis in Developing Countries
Groopman, J. D., Kensler, T. W., & Wild, C. P. (2008) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.29.020907.090859 · Cited by 296
The use of caffeine for enzyme assays: A critical appraisal
Kalow, W., & Tang, B.-K. (1993) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1993.63 · Cited by 287
Assessment of CYP1A2 Activity in Clinical Practice: Why, How, and When?
Faber, M. S., Jetter, A., & Fuhr, U. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto_973160.x · Cited by 283
Jerling, M., Lindström, L., Bondesson, U., & Bertilsson, L. (1994) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199408000-00006 · Cited by 281
Scott, E. E., White, M. A., He, Y. A., Johnson, E. F., Stout, C. D., & Halpert, J. R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403349200 · Cited by 279
Rostami-Hodjegan, A., Amin, A. M., Spencer, E. P., Lennard, M. S., Tucker, G. T., & Flanagan, R. J. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000106221.36344.4d · Cited by 278
Takagi, S., Nakajima, M., Mohri, T., & Yokoi, T. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709382200 · Cited by 278
Weinberger, M., & Hendeles, L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605233342107 · Cited by 274
Stiborová, M., Martínek, V., Rýdlová, H., Hodek, P., & Frei, E. (2002) · PubMed · Cited by 274
MicroRNAs Regulate CYP3A4 Expression via Direct and Indirect Targeting
Pan, Y.-Z., Gao, W., & Yu, A.-M. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.027680 · Cited by 272
Kagimoto, M., Heim, M., Kagimoto, K., Zeugin, T., & Meyer, U. A. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44890-3 · Cited by 265
A ligand for the aryl hydrocarbon receptor isolated from lung
Song, J., Clagett-Dame, M., Peterson, R. E., Hahn, M. E., Westler, W. M., Sicinski, R. R., & DeLuca, H. F. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.232562899 · Cited by 264
Ghotbi, R., Christensen, M., Roh, H.-K., Ingelman-Sundberg, M., Aklillu, E., & Bertilsson, L. (2007) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0288-2 · Cited by 264
Leflunomide or Methotrexate for Juvenile Rheumatoid Arthritis
Silverman, E., Mouy, R., Spiegel, L., Jung, L. K., Saurenmann, R. K., Lahdenne, P., Horneff, G., Calvo, I., Szer, I. S., Simpson, K., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041810 · Cited by 260
A survey of genetic and epigenetic variation affecting human gene expression
Pastinen, T., Sladek, R., Gurd, S., Sammak, A., Ge, B., Lepage, P., Lavergne, K., Villeneuve, A., Gaudin, T., Brändström, H., et al. (2004) · Physiological Genomics · doi:10.1152/physiolgenomics.00163.2003 · Cited by 260
Pharmacokinetics and Pharmacodynamics of Clozapine
Jann, M. W., Grimsley, S. R., Gray, E. C., & Chang, W.-H. (1993) · Clinical Pharmacokinetics · doi:10.2165/00003088-199324020-00005 · Cited by 257
Gunes, A., & Dahl, M.-L. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.5.625 · Cited by 256
Herbal bioactivation: The good, the bad and the ugly
Zhou, S., Koh, H.-L., Gao, Y., Gong, Z.-Y., & Lee, E. J. D. (2004) · Life Sciences · doi:10.1016/j.lfs.2003.09.035 · Cited by 256
Self-citationTime response of cytochrome P450 1A2 activity on cessation of heavy smoking*1
FABER, M. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.04.003 · Cited by 250
Clinical Pharmacokinetics of Leflunomide
Rozman, B. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241060-00003 · Cited by 250
Gurley, B. J., Gardner, S. F., Hubbard, M. A., Williams, D. K., Gentry, W. B., Cui, Y., & Ang, C. Y. W. (2005) · Drugs & Aging · doi:10.2165/00002512-200522060-00006 · Cited by 244
Resveratrol Is a Selective Human Cytochrome P450 1A1 Inhibitor
Chun, Y. J., Kim, M. Y., & Guengerich, F. P. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1152 · Cited by 243
Rasmussen (2002) · Pharmacogenetics · doi:10.1097/00008571-200208000-00008 · Cited by 241 · cited 3×
“In another study in 378 Danish twins, a closer correlation for CYP1A2 activity determined as caffeine urinary metabolic ratio was observed in monozygotic twins compared with that between dizygotic twins (Rasmussen et al., 2002).”
BackgroundResultInfluentialFrye, R. F., Matzke, G. R., Adedoyin, A., Porter, J. A., & Branch, R. A. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90114-4 · Cited by 241
Zhou, S.-F., Yang, L.-P., Zhou, Z.-W., Liu, Y.-H., & Chan, E. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9127-y · Cited by 238
Self-citationTucker, G. T., Lennard, M. S., Ellis, S. W., Woods, H. F., Cho, A. K., Lin, L. Y., Hiratsuka, A., Schmitz, D. A., & Chu, T. Y. Y. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90386-7 · Cited by 236
Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population
Solus, J. F., Arietta, B. J., Harris, J. R., Sexton, D. P., Steward, J. Q., McMunn, C., Ihrie, P., Mehall, J. M., Edwards, T. L., & Dawson, E. P. (2004) · Pharmacogenomics · doi:10.1517/14622416.5.7.895 · Cited by 236
Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes
Yamazaki, H., Inoue, K., Hashimoto, M., & Shimada, T. (1999) · Archives of Toxicology · doi:10.1007/s002040050588 · Cited by 235
Bulger, W. H., Muccitelli, R. M., & Kupfer, D. (1978) · Biochemical Pharmacology · doi:10.1016/0006-2952(78)90354-4 · Cited by 235
Ma, Q. (2001) · Current Drug Metabolism · doi:10.2174/1389200013338603 · Cited by 232
CYP1A2 genotype modifies the association between coffee intake and the risk of hypertension
Palatini, P., Ceolotto, G., Ragazzo, F., Dorigatti, F., Saladini, F., Papparella, I., Mos, L., Zanata, G., & Santonastaso, M. (2009) · Journal of Hypertension · doi:10.1097/hjh.0b013e32832ba850 · Cited by 230 · cited 1×
“Another study in 553 young Caucasian individuals screened for stage 1 hypertension has found that the risk of hypertension associated with coffee intake varied according to CYP1A2 genotype (Palatini et al., 2009).”
BackgroundStructures of Human Cytochrome P-450 2E1
Porubsky, P. R., Meneely, K. M., & Scott, E. E. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m805999200 · Cited by 224
Myrand, S., Sekiguchi, K., Man, M., Lin, X., Tzeng, R.-Y., Teng, C.-H., Hee, B., Garrett, M., Kikkawa, H., Lin, C.-Y., et al. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100482 · Cited by 224
Selectivity of Polycyclic Inhibitors for Human Cytochrome P450s 1A1, 1A2, and 1B1
Shimada, T., Yamazaki, H., Foroozesh, M., Hopkins, N. E., Alworth, W. L., & Guengerich, F. P. (1998) · Chemical Research in Toxicology · doi:10.1021/tx980090+ · Cited by 223
Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro
Richelson, E., & Nelson, A. (1984) · European Journal of Pharmacology · doi:10.1016/0014-2999(84)90478-3 · Cited by 223
METABOLISM AND DISPOSITION OF IMATINIB MESYLATE IN HEALTHY VOLUNTEERS
Gschwind, H.-P., Pfaar, U., Waldmeier, F., Zollinger, M., Sayer, C., Zbinden, P., Hayes, M., Pokorny, R., Seiberling, M., Ben-Am, M., et al. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.004283 · Cited by 223
Oxidation of Aflatoxin B1 by Bacterial Recombinant Human Cytochrome P450 Enzymes
Ueng, Y.-F., Shimada, T., Yamazaki, H., & Guengerich, F. P. (1995) · Chemical Research in Toxicology · doi:10.1021/tx00044a006 · Cited by 216
Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline
Kunze, K. L., & Trager, W. F. (1993) · Chemical Research in Toxicology · doi:10.1021/tx00035a009 · Cited by 216
Bryson, H. M., Fulton, B., & Benfield, P. (1996) · Drugs · doi:10.2165/00003495-199652040-00010 · Cited by 215
CYP1A Induction and Human Risk Assessment: An Evolving Tale of in Vitro and in Vivo Studies
Ma, Q., & Lu, A. Y. H. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.015826 · Cited by 215
Ring, B. J., Catlow, J., Lindsay, T. J., Gillespie, T., Roskos, L. K., Cerimele, B. J., Swanson, S. P., Hamman, M. A., & Wrighton, S. A. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12326-4 · Cited by 214
HepaRG Cells as an in Vitro Model for Evaluation of Cytochrome P450 Induction in Humans
Kanebratt, K. P., & Andersson, T. B. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.017418 · Cited by 214
Caffeine as a metabolic probe: Exploration of the enzyme-inducing effect of cigarette smoking
Kalow, W., & Tang, B.-K. (1991) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1991.8 · Cited by 213
Allele-specific gene expression uncovered
Knight, J. C. (2004) · Trends in Genetics · doi:10.1016/j.tig.2004.01.001 · Cited by 211
Clinical Pharmacogenetics and Potential Application in Personalized Medicine
Zhou, S.-F., Ming Di, Y., Chan, E., Du, Y.-M., Chow, V., Xue, C., Lai, X., Wang, J.-C., Li, C., Tian, M., et al. (2008) · Current Drug Metabolism · doi:10.2174/138920008786049302 · Cited by 211
Self-citationDisposition and biotransformation of the antipsychotic agent olanzapine in humans.
Kassahun, K., Mattiuz, E. L., Nyhart, E. H., Obermeyer, B. D., Gillespie, T. A., Murphy, A., Rm, G., Tupper, D., Callaghan, J. T., & Lemberger, L. (1997) · PubMed · Cited by 211
Thioridazine for schizophrenia
Fenton, M., Rathbone, J., & Reilly, J. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001944.pub2 · Cited by 209
Campbell, M. E., Grant, D. M., Inaba, T., & Kalow, W. (1987) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)06689-9 · Cited by 208
Characterization of the Ah Receptor-associated Protein, ARA9
Carver, L. A., LaPres, J. J., Jain, S., Dunham, E. E., & Bradfield, C. A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.50.33580 · Cited by 208
Berger, W., De Chandt, M. T. M., & Cairns, C. B. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01320.x · Cited by 205
Methoxychlor as a Model for Environmental Estrogens
Cummings, A. M. (1997) · Critical Reviews in Toxicology · doi:10.3109/10408449709089899 · Cited by 205
Bioactivation of mutagens via sulfation
Glatt, H. (1997) · The FASEB Journal · doi:10.1096/fasebj.11.5.9141497 · Cited by 200
Identification of P450 enzymes involved in metabolism of verapamil in humans
Kroemer, H., Gautier, J.-C., Beaune, P., Henderson, C., Roland Wolf, C., & Eichelbaum, M. (1993) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/bf00169164 · Cited by 200
Bock, K. W., Schrenk, D., Forster, A., Griese, E.-U., M??rike, K., Brockmeier, D., & Eichelbaum, M. (1994) · Pharmacogenetics · doi:10.1097/00008571-199408000-00005 · Cited by 199
Caffeine metabolism by human hepatic cytochromes p450: Contributions of 1A2, 2E1 and 3A isoforms
Tassaneeyakul, W., Birkett, D. J., McManus, M. E., Tassaneeyakul, W., Veronese, M. E., Andersson, T., Tukey, R. H., & Miners, J. O. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90304-2 · Cited by 198
Kreth, K.-P., Kovar, K.-A., Schwab, M., & Zanger, U. M. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00284-7 · Cited by 198
A role for Asp-251 in cytochrome P-450cam oxygen activation.
Gerber, N. C., & Sligar, S. G. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)41772-8 · Cited by 195
Yeh, R. F., Gaver, V. E., Patterson, K. B., Rezk, N. L., Baxter-Meheux, F., Blake, M. J., Eron, J. J., Klein, C. E., Rublein, J. C., & Kashuba, A. D. M. (2006) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000219774.20174.64 · Cited by 194
Ohyama, K., Nakajima, M., Suzuki, M., Shimada, N., Yamazaki, H., & Yokoi, T. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00134.x · Cited by 190
METABOLISM OF RETINOIDS AND ARACHIDONIC ACID BY HUMAN AND MOUSE CYTOCHROME P450 1B1
Choudhary, D., Jansson, I., Stoilov, I., Sarfarazi, M., & Schenkman, J. B. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.8.840 · Cited by 190
Lampe, J. W., King, I. B., Li, S., Grate, M. T., Barale, K. V., Chen, C., Feng, Z., & Potter, J. D. (2000) · Carcinogenesis · doi:10.1093/carcin/21.5.157 · Cited by 190
Imiquimod and resiquimod as novel immunomodulators
Dockrell, D. H. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/48.6.751 · Cited by 185
Yamazaki, H., Shaw, P. M., Guengerich, F. P., & Shimada, T. (1998) · Chemical Research in Toxicology · doi:10.1021/tx970217f · Cited by 182
Komoroski, B. J., Zhang, S., Cai, H., Hutzler, J. M., Frye, R., Tracy, T. S., Strom, S. C., Lehmann, T., Ang, C. Y. W., Cui, Y. Y., et al. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.5.512 · Cited by 181
Aklillu, E., Carrillo, J. A., Makonnen, E., Hellman, K., Pitarque, M., Bertilsson, L., & Ingelman-Sundberg, M. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.3.659 · Cited by 181
Tantcheva‐Poór, I., Zaigler, M., Rietbrock, S., & Fuhr, U. (1999) · PubMed · Cited by 180
Chen, H., Howald, W. N., & Juchau, M. R. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15367-6 · Cited by 179
The effect of variable cigarette consumption on the interaction with clozapine and olanzapine
Haslemo, T., Eikeseth, P. H., Tanum, L., Molden, E., & Refsum, H. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0209-9 · Cited by 178
Wetzel, H., Anghelescu, I. G., Szegedi, A., Wiesner, J., Weigmann, H., Härtter, S., & Hiemke, C. (1998) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199802000-00002 · Cited by 178
Physiological and metabolic functions of melatonin
Barrenetxe, J., Delagrange, P., & Martínez, J. A. (2004) · Journal of Physiology and Biochemistry · doi:10.1007/bf03168221 · Cited by 177
Yueh, M.-F., Huang, Y.-H., Hiller, A., Chen, S., Nguyen, N., & Tukey, R. H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300645200 · Cited by 177
van der Weide, J., Steijns, L. S., & van Weelden, M. J. (2003) · Pharmacogenetics · doi:10.1097/00008571-200303000-00006 · Cited by 176
Engel, G., Hofmann, U., Heidemann, H., Cosme, J., & Eichelbaum, M. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90001-6 · Cited by 176
Olesen, O. V., & Línnet, K. (2001) · The Journal of Clinical Pharmacology · doi:10.1177/00912700122010717 · Cited by 176
Ma, B., Prueksaritanont, T., & Lin, J. H. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15118-5 · Cited by 176
Sachse, C., Bhambra, U., Smith, G., Lightfoot, T. J., Barrett, J. H., Scollay, J., Garner, R. C., Boobis, A. R., Wolf, C. R., Gooderham, N. J., et al. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01733.x · Cited by 174
Ikeya, K., Jaiswal, A. K., Owens, R. A., Jones, J. E., Nebert, D. W., & Kimura, S. (1989) · Molecular Endocrinology · doi:10.1210/mend-3-9-1399 · Cited by 174
Structural Analysis of CYP2R1 in Complex with Vitamin D3
Strushkevich, N., Usanov, S. A., Plotnikov, A. N., Jones, G., & Park, H.-W. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.03.065 · Cited by 173
Thalidomide metabolism by the CYP2C subfamily.
Ando, Y., Fuse, E., & Figg, W. D. (2002) · PubMed · Cited by 171
Turesky, R. J., Constable, A., Richoz, J., Varga, N., Markovic, J., Martin, M. V., & Guengerich, F. P. (1998) · Chemical Research in Toxicology · doi:10.1021/tx980022n · Cited by 170
On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics
Lewis, D. F. V. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00335-x · Cited by 168
Detection of Gene × Gene Interactions in Genome-Wide Association Studies of Human Population Data
Musani, S. K., Shriner, D., Liu, N., Feng, R., Coffey, C. S., Yi, N., Tiwari, H. K., & Allison, D. B. (2007) · Human Heredity · doi:10.1159/000099179 · Cited by 168
Maurel, P. (1996) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00417-6 · Cited by 167
Masubuchi, Y., Hosokawa, S., Horie, T., Suzuki, T., Ohmori, S., Kitada, M., & Narimatsu, S. (1994) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08435-1 · Cited by 166
Metabolism of theophylline by cDNA‐expressed human cytochromes P‐450.
Ha, H., Chen, J., Freiburghaus, A., & Follath, F. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb04455.x · Cited by 166
Boberg, E. W., Miller, E. C., MILLER, J. A., Poland, A., & Liem, A. (1983) · PubMed · Cited by 166
Melendez-Colon, V. J., Luch, A., Seidel, A., & Baird, W. M. (1999) · Carcinogenesis · doi:10.1093/carcin/20.10.1885 · Cited by 165
Evans, B. R., Karchner, S. I., Allan, L. L., Pollenz, R. S., Tanguay, R. L., Jenny, M. J., Sherr, D. H., & Hahn, M. E. (2008) · Molecular Pharmacology · doi:10.1124/mol.107.040204 · Cited by 163
Pharmacological Rationale for the Clinical Use of Caffeine
Sawynok, J. (1995) · Drugs · doi:10.2165/00003495-199549010-00004 · Cited by 161
The 90-kDa heat shock protein is essential for Ah receptor signaling in a yeast expression system.
Carver, L. A., Jackiw, V, & Bradfield, C. A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)43782-9 · Cited by 159
Cyp1a2(-/-) null mutant mice develop normally but show deficient drug metabolism.
Liang, H. C., Li, H., McKinnon, R. A., Duffy, J. J., Potter, S. S., Puga, A., & Nebert, D. W. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.4.1671 · Cited by 159
Wen, X., Wang, J., Neuvonen, P. J., & Backman, J. T. (2001) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-001-0396-3 · Cited by 157
Petrulis, J. R., Kusnadi, A. R., Ramadoss, P., Hollingshead, B. D., & Perdew, G. H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209331200 · Cited by 157
Shimada, T., Gillam, E. M. J., Oda, Y., Tsumura, F., Sutter, T. R., Guengerich, F. P., & Inoue, K. (1999) · Chemical Research in Toxicology · doi:10.1021/tx990028s · Cited by 156
Granfors, M. T., Backman, J. T., Neuvonen, M., & Neuvonen, P. J. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.08.018 · Cited by 155
Therapeutic Drugs that Behave as Mechanism-Based Inhibitors of Cytochrome P450 3A4
Zhou, S., Chan, E., Lim, L. Y., Boelsterli, U. A., Li, S., Wang, J., Zhang, Q., Huang, M., & Xu, A. (2004) · Current Drug Metabolism · doi:10.2174/1389200043335450 · Cited by 155
Self-citationWiseman, R. W., Miller, E. C., MILLER, J. A., & Liem, A. (1987) · PubMed · Cited by 154
Okey, A. B., Vella, L. M., & Harper, P. A. (1989) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)11526-5 · Cited by 154
Dominant Contribution of P450 3A4 to the Hepatic Carcinogenic Activation of Aflatoxin B1
Kamdem, L. K., Meineke, I., Gödtel‐Armbrust, U., Brockmöller, J., & Wojnowski, L. (2006) · Chemical Research in Toxicology · doi:10.1021/tx050358e · Cited by 153
Rasmussen, B., Mäenpää, J., Pelkonen, O., Loft, S. H., Poulsen, H. E., Lykkesfeldt, J., & Brøsen, K. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb04422.x · Cited by 151
ABCB1 and Cytochrome P450 Polymorphisms
Sirot, E. J., Knežević, B., Morena, P., Harenberg, S., Oneda, B., Crettol, S., Ansermot, N., Baumann, P., & Eap, C. B. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181acc372 · Cited by 148
Rawden, H. C., Kokwaro, G. O., Ward, S. A., &, & Edwards, G. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00170.x · Cited by 146
Chang, T. K. H., Chen, J., & Lee, W. B. K. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29205-3 · Cited by 145
Hughes, A. N., O'Brien, M. E. R., Petty, W. J., Chick, J. B., Rankin, E., Woll, P. J., Dunlop, D., Nicolson, M., Boinpally, R., Wolf, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.3995 · Cited by 144 · cited 1×
“Clinical studies have shown that smoking can increase the clearance and reduce the plasma concentrations of theophylline, melatonin, clozapine, riluzole, lidocaine, verapamil, erlotinib, fluvoxamine, and ropivacaine (Hughes et al., 2009; Kroon, 2007; Sugahara et al., 2009).”
BackgroundYamazaki, H., Inoue, K., Shaw, P. M., Checovich, W. J., Guengerich, F. P., & Shimada, T. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37072-7 · Cited by 142
Pedrosa, R. C., Daujat‐Chavanieu, M., Pichard‐Garcia, L., Ourlin, J.-C., Clair, P., Gervot, L., Lesca, P., Domergue, J., Joyeux, H., & Fourtanier, G. (1994) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38702-1 · Cited by 142
Nakajima, M., Yokoi, T., Mizutani, M., Shin, S., Kadlubar, F. F., & Kamataki, T. (1994) · PubMed · Cited by 141
Zhou, S., Xue, C. C., Yu, X., & Wang, G. (2007) · Current Drug Metabolism · doi:10.2174/138920007781368863 · Cited by 140
Self-citationUttamsingh, V., Lu, C., Miwa, G. T., & Gan, L.-S. L. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.005710 · Cited by 139
Comparative inhibition of human cytochromes P450 1A1 and 1A2 by flavonoids.
Zhai, S., Dai, R., Friedman, F. K., & Vestal, R. E. (1998) · PubMed · Cited by 138
Shimizu, T., Tateishi, T., HATANO, M., & Fujii-Kuriyama, Y. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)67801-4 · Cited by 137
Fontana, R. J., Lown, K. S., Paine, M. F., Fortlage, L., Santella, R. M., Felton, J. S., Knize, M. G., Greenberg, A., & Watkins, P. B. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70554-8 · Cited by 137
Kanebratt, K. P., Diczfalusy, U., Bäckström, T., Sparve, E., Bredberg, E., Böttiger, Y., Andersson, T., & Bertilsson, L. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.132 · Cited by 136
Carrillo, J. A., Christensen, M., Ramos, S., Alm, C., Dahl, M., Benítez, J., & Bertilsson, L. (2000) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200008000-00008 · Cited by 136
Piver, B., Fer, M., Vitrac, X., Mérillon, J., Dréano, Y., Berthou, F., & Lucas, D. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.05.008 · Cited by 136
Characterization of human liver cytochromes P-450 involved in theophylline metabolism.
Sarkar, M. A., Hunt, C. M., Guzelian, P. S., & Karnes, H. T. (1992) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08515-0 · Cited by 135
(R)-, (S)-, and Racemic Fluoxetine N-Demethylation by Human Cytochrome P450 Enzymes
Margolis, J. M., O’Donnell, J. P., Mankowski, D. C., Ekins, S., & Obach, R. S. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0026-895x(24)12048-2 · Cited by 134
Phenotypic polymorphism and gender‐related differences of CYP1A2 activity in a Chinese population
Ou‐Yang, D., Huang, S., Wang, W., Xie, H., Xu, Z., Shu, Y., & Zhou, H. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00128.x · Cited by 133
Rost, K. L., Brösicke, H., Brockmöller, J., Scheffler, M., Helge, H., & Roots, I. (1992) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1992.126 · Cited by 132
MARTINEZ, C., Albet, C., Agúndez, J. A. G., HERRERO, E., Carrillo, J. A., MARQUEZ, M., Benítez, J., & ORTIZ, J. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70129-3 · Cited by 132
Pearce, R. E., Vakkalagadda, G. R., & Leeder, J. S. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.11.1170 · Cited by 132
Drug Interactions and the Cytochrome P450 System
Brøsen, K. (1995) · Clinical Pharmacokinetics · doi:10.2165/00003088-199500291-00005 · Cited by 131
Hockley, S. L., Arlt, V. M., Brewer, D. S., Giddings, I., & Phillips, D. H. (2006) · BMC Genomics · doi:10.1186/1471-2164-7-260 · Cited by 131
Ryu, J. Y., Song, I., Sunwoo, Y. E., SHON, J., Liu, K. H., Cha, I., & Shin, J. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100187 · Cited by 129
Wenzlaff, A. S., Coté, M. L., Bock, C. H., et al. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi191 · Cited by 129
Sertraline N-Demethylation Is Catalyzed by Multiple Isoforms of Human Cytochrome P-450 In Vitro
Kobayashi, K., Ishizuka, T., Shimada, N., Yoshimura, Y., Kamijima, K., & Chiba, K. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15222-1 · Cited by 127
Cited by
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
“Due to its relatively high expression in liver, CYP1A2 plays a significant role in the metabolism of several clinically important drugs (Gunes & Dahl, 2008; Zhou et al., 2009).”
BackgroundCornelis, M. C., Monda, K. L., Yu, K., Paynter, N., Azzato, E. M., Bennett, S. N., Berndt, S. I., Boerwinkle, E., Chanock, S., Chatterjee, N., et al. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1002033 · Cited by 228
Nordestgaard, A. T., Thomsen, M., & Nordestgaard, B. G. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv083 · Cited by 189
Koonrungsesomboon, N., Khatsri, R., Wongchompoo, P., & Teekachunhatean, S. (2018) · The Pharmacogenomics Journal · doi:10.1038/s41397-017-0011-3 · Cited by 100
Dose-response of berberine on hepatic cytochromes P450 mRNA expression and activities in mice
Guo, Y., Pope, C., Cheng, X., Zhou, H., & Klaassen, C. D. (2011) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2011.08.058 · Cited by 77
“AhR activation and the significant induction of Cyp1a enzyme activity can increase the biotransformation of various procarcinogens and promutagens to carcinogens and mutagens that covalently bind to important functional macromolecules such as DNA, which can result in carcinogenic transformation of cells (Zhou et al.,…”
Background
Metadata
- Authors
- Zhou, S.-F., Wang, B., Yang, L.-P., & Liu, J.-P.
- Venue
- Drug Metabolism Reviews
- Publisher
- Informa UK Limited
- Published
- 2009-12-04
- Volume
- 42
- Issue
- 2
- Pages
- 268-354
- ISSN
- 0360-2532 (ISSN-L)
- 1097-9883
- OpenAlex
- W2042005699
- Cited by
- 262
- References
- 515
- FWCI
- 13.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.